Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Metastatic Malignant Neoplasm in the Lung: early-phase trial registry

7 of 13 indexed Metastatic Malignant Neoplasm in the Lung trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 7 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Metastatic Malignant Neoplasm in the Lung: 13 US clinical trials tracked, 7 recruiting.

Metastatic Malignant Neoplasm in the Lung is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition metastatic-malignant-neoplasm-in-the-lung

OPEN 7 | RECR 54% | LATE 2 | EARLY 7 | RANK #1315 | SPON 4

Nearest open-share peer: Advanced Renal Cell Carcinoma (54% recruiting · 13 trials)

ACL Injury61.5%Metastatic Malignant Neo (th…54%Acute Biphenotypic Leukemia46.2%Accidental Falls30.8%Actinic Keratoses23.1%
Open-enrollment share among volume-matched conditions near Metastatic Malignant Neoplasm in the Lung

Metastatic Malignant Neoplasm in the Lung lists 7 open slots (54% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Metastatic Malignant Neoplasm in the Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Metastatic Malignant Neoplasm in the Lung is recruiting above its size-band peers.

    7 of 13 indexed trials (53.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Metastatic Malignant Neoplasm in the Lung research.

    M.D. Anderson Cancer Center accounts for 4 of 13 trials (30.8%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Metastatic Malignant Neoplasm in the Lung trials plan to enrol fewer than 100 people.

    Median target enrolment is 41 among the 13 trials that report a genuine target (sentinel values excluded). 12 of those (92.3%) plan for fewer than 100 participants.

  4. Metastatic Malignant Neoplasm in the Lung research is mostly interventional.

    11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 21Phase 32

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1 99 participants

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Roswell Park Cancer Institute

NCT03965234

RECRUITING NA 70 participants

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

Northwestern University

NCT05802186

RECRUITING Phase 3 62 participants

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Children's Oncology Group

NCT05235165

RECRUITING 40 participants

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)

Mayo Clinic

NCT06482073

RECRUITING Phase 1 40 participants

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

M.D. Anderson Cancer Center

NCT05039632

RECRUITING Phase 1 30 participants

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stanford University

NCT03582124

RECRUITING NA 30 participants

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

M.D. Anderson Cancer Center

NCT03422302

ACTIVE NOT RECRUITING Phase 3 312 participants

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

NCT02306161

ACTIVE NOT RECRUITING Phase 1 70 participants

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

M.D. Anderson Cancer Center

NCT01590069

ACTIVE NOT RECRUITING Early Phase 1 27 participants

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Julie L. Sutcliffe, Ph.D

NCT03164486

COMPLETED 75 participants

4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

M.D. Anderson Cancer Center

NCT00862680

COMPLETED Phase 2 41 participants

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

National Cancer Institute (NCI)

NCT02484443

COMPLETED Phase 1 20 participants

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

University of Washington

NCT03749460

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1
Phase 3 2

Named interventions

Most-linked intervention names on Metastatic Malignant Neoplasm in the Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Computed Tomography Procedure
3 trials
Laboratory Biomarker Analysis Other
2 trials
4D PET Scan Procedure
1 trials
4-Dimensional Computed Tomography Procedure
1 trials
Etoposide Phosphate Drug
1 trials
Aerosolized Aldesleukin Biological
1 trials
Dinutuximab Biological
1 trials
Pharmacological Study Other
1 trials

US sites by state

Facility locations filed on Metastatic Malignant Neoplasm in the Lung trials. A trial with sites in several states counts in each.

California 5 trials
Texas 4 trials
Arizona 3 trials
Arkansas 3 trials
Alabama 3 trials
Alaska 2 trials
Washington 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Metastatic Malignant Neoplasm in the Lung page

13 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Metastatic Malignant Neoplasm in the Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most Metastatic Malignant Neoplasm in the Lung trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Malignant Neoplasm in the Lung condition card totals 13 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.